The Rotation of Disinfectants Principle: True or False? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Rotation of Disinfectants Principle: True or False?
The author defines sanitizers, disinfectants, and antibiotics, and examines the question of whether the rotation of disinfectants is scientifically warranted.

Pharmaceutical Technology
Volume 33, Issue 2, pp. 58-71

Quinolones form a complex with DNA and DNA gyrase or Top IV (84). Quinolones inhibit the release of DNA from DNA gyrase, prevent the rebinding of DNA strands, and break DNA (84, 85). As a rule of thumb, gram-negative bacterial activity correlates with the inhibition of DNA gyrase, and gram-positive bacterial activity corresponds with the inhibition of Top IV.

Resistance to quinolones results from mutations in the genes' encoding for DNA gyrase and Top IV. Gene mutations change the primary structure of DNA gyrase and Top IV. These small changes prevent the enzymes from binding to quinolones and forming a quinolone–DNA–DNA gyrase (or Top IV) complex.

Inhibitors of bacterial-wall synthesis (β-lactam). The β-lactam antibiotics are natural and semisynthetic compounds that inhibit several enzymes associated with the final step of peptidoglycan synthesis and assembly. These antibiotics are derived from the β-lactam structure: a four-tiered ring in which the β-lactam bond resembles a peptide bond. The β-lactam group includes the following five subgroups:

  • Penicillins (e.g., 6-aminopenicillanic acid derivatives)
  • Cephalosporins (e.g., 7-aminocephalosporanic acid derivatives)
  • Cephalosporin-related agents (e.g., oxacephems and cephamycins)
  • Carbapenems (e.g., imipenem)
  • Monobactams (e.g., aztreonam) (86).

The β-lactam antibiotics inhibit bacterial-wall synthesis. The targets for β-lactam antibiotics are the penicillin-binding proteins (PBPs), which are permanently inactivated. The PBPs have transpeptidase or carboxypeptidase activity that regulates cell size and shape. In addition, PBPs are involved in cell division through the manufacture of new bacterial walls. Bacteria have many PBPs, and each one has a separate function.

The following are the four major mechanisms of resistance to β-lactam antibiotics:

  • Inactivation by β-lactamases
  • Modification of target PBPs
  • Efflux pumps
  • Reduced OM permeability (86, 87).

Antimetabolites: inhibitors of folic-acid synthesis. The specificity of these antibiotics stems from the fact that bacteria cannot use preformed folic acid and must synthesize their own folic acid (88). Mammalian cells use folic acid from exogenous sources.

Sulfonamides. These antibiotics are analogues of paraaminobenzoic acid (PABA). Sulfonamides block bacterial reproduction by acting as competitive inhibitors of PABA in the folic-acid metabolism cycle. The target molecule is dihydropteroate synthase (DHPS). Inhibition of this enzyme results in the depletion of tetrahydrofolate (89). Therefore, sulfonamides are bacteriostatic. Sulfonamides possess a broad range of activity against gram-positive and gram-negative bacteria. Sulfamethoxazole is the most popular drug in this subgroup of antibiotics.

Resistance is common, and resistance to one sulfonamide provides resistance to all. Sulfamethoxazole resistance is the result of either chromosomal mutations in the DHPS gene that yield drug-resistant forms of DHPS or efflux pumps (90–92).

Sulfanilamides. These antibiotics bind to dihydrofolate reductase (DHFR) and inhibit the formation of tetrahydrofolic acid. They are thus bacteriostatic. Their spectrum of activity covers gram-positive and gram-negative bacteria. Trimethoprim (TMP) is representative of this subgroup.

The major causes of TMP resistance are the following:

  • Production of an altered DHFR that lacks the capacity to bind sulfanilamides
  • Decrease in drug uptake
  • Efflux pumps
  • Overproduction of the normal DHFR (93–95).

Development of resistance to antibiotics

Resistance to antibiotics develops in only two major ways. The antibiotic, acting as a selective agent, can help propagate resistance microorganisms. In other cases, particular genes provide resistance. If either of these two conditions is not present, resistant bacteria are not developed.

Bacterial resistance to antibiotics is a natural outcome of selective pressure or evolution. Bacterialike organisms arose more than three billion years ago and have been constantly faced with natural products that have antibacterial activity (i.e., antibiotics) and related organic molecules. Bacteria have acquired resistance genes to survive. When a random mutation provides a bacterium with a resistance gene, its progeny will have a survival advantage and proliferate despite the presence of substances that inhibit or kill competing microorganisms. Resistance genes are passed to other bacteria through various gene-transfer processes. In general, bacterial resistance to antibiotics is either intrinsic (i.e., resulting from native genes) or acquired (i.e., resulting from new genes).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here